

TABLE OF CONTENTS

Certificate	iii
Declaration by the Candidate	iv
Copyright Transfer Certificate	v
Acknowledgements	vi-ix
Contents	x-xvii
List of Figures	xviii-xxi
List of Tables	xxii
List of Symbols and Abbreviations	xxiv-xxv
Preface	xxvi-xxix
Chapter 1: Introduction and Literature Review	1-53
1.1 Introduction	1
1.2 Understanding the mechanisms underlying chemotherapy-induced neuropathic pain	3
1.2.1 Vincristine-induced peripheral neuropathy	3
1.2.2 Cisplatin-induced neuropathic pain	5
1.2.3 Peripheral sensitization	7
1.2.4 Central sensitization	9
1.2.5 Neuronal Damage and Axonal Dysfunction	10
1.2.6 Oxidative Stress, Mitochondrial Dysregulation and Inflammation	11
1.2.6 Increase ion channel activity	12
1.3 Pharmacotherapeutics for the treatment of CINP and their limitations	15
1.3.1 Tricyclic antidepressants (TCAs)	16
1.3.2 Serotonin–noradrenaline reuptake inhibitors (SNRIs)	16
1.3.3 Anticonvulsants	17
1.3.4 Opioids and NSAIDs	18
1.3.5 Anti-inflammatory compounds	18
1.4 Perspectives from preclinical data	20
1.4.1 TRP channel inhibition	20
1.4.2 TRPA1 and TRPV4 modulation	21
1.4.3 Antioxidants and neuroprotective agents	22
1.4.4 NMDA antagonists	23

1.5 Other pharmacological treatment	24
1.6 TRP channels as a potential drug target for CINP	25
1.6.1 Growing significance of TRPV1 channels in CINP	26
1.6.2 Crucial role of TRPA1 channels as regulators in CINP	28
1.6.3 Unveiling the significance of TRPM8 channel in CINP	29
1.6.4 TRP channels and cytokines/chemokines interplay in CINP	30
1.7 NMDA receptors system: A key player in the pathophysiology of CINP	33
1.7.1 NMDA mediated central sensitization across the ascending and descending pain pathways	33
1.7.2 NR2B assembly subunit of NMDA critically mediates CINP	38
1.8 Animal models for CINP	40
1.9 Drug failures stemming from preclinical model incompatibility	41
1.10 Bergenin: A potential therapeutic breakthrough for treatment of chronic pain	43
1.11 siRNA as a promising approach for the treatment of CINP	44
1.11.1 siRNA structure and function: a brief overview	44
1.12 Collecting evidence supporting TRPA1 channels as a potential therapeutic target for CINP	46
1.13 Current status of siRNA interventions as a near-future therapeutic tool	48
1.14 Current challenges and future prospects: a roadmap for advancement of siRNA therapeutics	50
1.15 Nano-carriers as promising candidates for siRNA delivery	51
Chapter 2: Rationale, Objectives and Plan of Work	54-63
2.1 Rationale	54
2.2 Objectives	56
2.3 Plan of work	58
2.3.1 Study I	58
2.3.2 Study II	59
2.3.3 Study III	62

Chapter 3: Materials & Methods	64-93
3.1 Drugs, chemicals and antibodies	64
3.2 Equipment and software	66
3.3 <i>In-vivo</i> studies	69
3.3.1 Experimental animals	69
3.3.2 Ethical committee approval	69
3.3.3 Animal model of chemotherapy induced neuropathic pain	69
3.3.3.1 Paclitaxel Model of Chemotherapy-Induced Neuropathic Pain	69
3.3.3.2 Combination chemotherapy model of chemotherapy-induced neuropathic pain	70
3.3.4 Experimental design	70
3.3.5 Intrathecal siRNA knockdown of TRPA1 expression	72
3.3.6 Preparation of liposomal formulation	73
3.3.6.1 Preparation of blank and TRPA1 siRNA based liposomal formulation	73
3.3.7 Characterization of blank and TRPA1 siRNA based liposomal formulation	74
3.3.7.1 Determination of particle size, polydispersity index and zeta potential	74
3.3.7.2 Morphological characterization	74
3.3.7.3 Infra-red (IR) spectroscopy	75
3.3.7.4 X-ray photoelectron spectroscopy (XPS) analysis	75
3.3.7.5 Thermogravimetric analysis	76
3.3.7.6 Differential scanning calorimeter analysis	76
3.3.8 Animal pain behavior tests	76
3.3.8.1 Tail flick test: Analgesic assay	76
3.3.8.2 Tail clip test	77
3.3.8.3 Pinprick test	77
3.3.8.4 Hargreaves test: Thermal hyperalgesia	77
3.3.8.5 von-Frey hair Test: Static allodynia	78

3.3.8.6	Paint brush test: Dynamic mechanical test	79
3.3.8.7	Cold plate test: Cold hyperalgesia test	79
3.3.8.8	Acetone evaporation test	80
3.3.8.9	Conditioned place preference: Spontaneous ongoing pain assay	80
3.3.9	Behavioral neurotoxicity assays	81
3.3.9.1	Rota-rod test	81
3.3.9.2	Open field test	82
3.3.10	Tissue harvesting and storage	82
3.3.11	Biochemical assays	82
3.3.11.1	Lipid peroxidation	82
3.3.11.2	Nitrite estimation	83
3.3.11.3	Glutathione estimation	83
3.3.11.4	Quantification of superoxide dismutase (SOD)	84
3.3.12	Evans blue assay	84
3.3.13	Molecular biology studies	85
3.3.13.1	Western blot analysis	85
3.3.13.2	Reverse transcription polymerase chain reaction (RT PCR) analysis	87
3.4	<i>In-silico</i> study	89
3.4.1	Homology modeling	89
3.4.1.1	NCBI Database and Sequence Retrieval	89
3.4.1.2	Sequence Alignment	90
3.4.1.3	Structure prediction and homology modelling of TRPA1 and TRPM8	90
3.4.1.4	Structure-based virtual screening	91
3.4.1.5	Molecular dynamics simulation NCBI Database and Sequence Retrieval	92
3.5	Statistical analysis	93
Chapter 4:	Development and Pharmacological Validation of Clinically Mimicable Animal Model of Combined Chemotherapy-Induced Neuropathic Pain	94-135
4.1	Introduction	94

4.2 Experimental procedure	96
4.3 Results and discussion	98
4.3.1 Effect of combined chemotherapy on daily body weight changes in rats	98
4.3.2 Combination chemotherapy causes pain like behaviours in rats	100
4.3.2.1 Combination chemotherapy causes thermal and mechanical hypersensitivity in rats	100
4.3.2.2 Combined chemotherapy develops cold hypersensitivity in rats	103
4.3.3 Modulation of TRP channels, NR2B, neuropeptides and inflammatory signaling in DRG and Spinal cord of neuropathic rats	105
4.3.3.1 Combined chemotherapy upregulates TRP Channels mRNA expression in DRG and spinal cord of rats	105
4.3.3.2 Combined chemotherapy significantly upregulated NR2B mRNA expression in DRG and spinal tissue	107
4.3.3.3 Combined chemotherapy increases neuropeptides levels in the DRG and spinal cord of rats	109
4.3.3.4 Combined chemotherapy-induced neuro-inflammation in DRG and spinal cord of rats	111
4.3.4 Biochemical observations and interpretation	112
4.3.4.1 Combined chemotherapy suppressed the antioxidant enzyme activity in sciatic nerve of rats	112
4.3.4.2 Combined chemotherapy increases MDA and Nitrite levels in sciatic nerve of rats	114
4.3.5 Pharmacological validation of novel combined chemotherapy model of CINP	116
4.3.5.1 Gabapentin does not affect body weight in chemotherapy treated rats	116
4.3.5.2 Gabapentin alleviates chemotherapy-induced mechanical and thermal pain behaviour in rats	117

4.3.5.3	Gabapentin alleviates chemotherapy-induced cold pain behaviour in rats	120
4.3.5.4	Gabapentin suppressed mRNA expression of TRPV1, TRPA1 and TRPM8 in DRG and spinal cord tissue of neuropathic rats	122
4.3.5.5	Gabapentin treatment decreases NR2B mediated Iba1 expressions in DRG and spinal cord of neuropathic rats	124
4.3.5.6	Gabapentin treatment decreases ICAM-1 expression in DRG and spinal cord of neuropathic rats	126
4.3.5.7	Gabapentin treatment suppressed CGRP and Substance P in CINP rats	127
4.3.5.8	Gabapentin treatment suppressed neuro-inflammatory cascade in neuropathic rats	130
4.3.5.9	Gabapentin treatment alleviated oxidative stress and increased antioxidant enzyme activity in sciatic nerve of neuropathic rats	132
4.3.6	Overall Summary and key findings	134
4.4	Outcomes	135
Chapter 5:	Modulation of TRPA1/TRPV1/NR2B signaling by Bergenin in a Rat Model of Chemotherapy-Induced Neuropathic Pain	136-180
5.1	Introduction	136
5.2	Experimental Design	138
5.3	Results and discussion	139
5.3.1	Assessment of general toxicity	139
5.3.2	Bergenin ameliorates chemotherapy-induced mechanical allodynia (static and dynamic) in rats	140
5.3.3	Bergenin alleviates chemotherapy-induced thermal hyperalgesia in rats	142
5.3.4	Bergenin attenuates mechanical hyperalgesia in rats administered with combination chemotherapy	143

5.3.5	Bergenin treatment decreased chemotherapy-induced cold pain behavior in rats	144
5.3.6	Bergenin did not altered the pain threshold of healthy naïve rats	147
5.3.7	Bergenin attenuates spontaneous ongoing pain in neuropathic rats without causing drug addiction	148
5.3.8	Bergenin treatment does not cause locomotor impairment and motor in-coordination in rats	153
5.3.9	Bergenin modulates mRNA and protein expressions of TRP channels in DRG and spinal cord of neuropathic rats	155
5.4	Bergenin decreased NR2B mediated ICAM-1 and Iba1 expression in DRG and spinal cord of neuropathic rats	158
5.5	Bergenin restored blood-spinal cord barrier integrity in chemotherapy-administered rats	161
5.6	Bergenin attenuates oxido-inflammatory cascade in DRG and spinal cord of neuropathic rats	164
5.7	<i>In-silico</i> studies	167
5.7.1	Homology modelling	167
5.7.2	Molecular Docking	169
5.7.3	Molecular Dynamics Simulation	171
5.7.4	Overall Summary	178
5.7.4	Outcomes	180
Chapter 6:	Development of TRPA1 siRNA Based Nanoforumulation for the Treatment of Chemotherapy-Induced Neuropathic Pain	181-211
6.1	Introduction	181
6.2	Experimental design	183
6.3	Results and discussion	184
6.3.1	Validation of TRPA1-siRNA knockdown efficacy in rats	184
6.3.2	Physicochemical Characterization of blank liposome and TRPA1 siRNA loaded liposome	187
6.3.3	Scanning electron microscopy (SEM) Analysis	189

6.3.4 Atomic Force Microscopy (AFM) analysis	191
6.3.5 Fourier-transform infrared analysis of liposome	192
6.3.6 Differential Scanning Calorimetry (DSC) analysis	194
6.3.7 Thermogravimetric Analysis (TGA) of liposome formulation	195
6.3.8 X-ray photoelectron spectroscopy (XPS) analysis	196
6.4 Agarose gel electrophoresis for entrapment efficiency of TRPA1 siRNA liposome	198
6.5 TRPA1 siRNA based liposomal formulation attenuates chemotherapy-induced mechanical and cold allodynia in rats	200
6.6 TRPA1 siRNA based liposomal formulation downregulates TRPA1 and Iba1 protein expressions in spinal cord of neuropathic rats	203
6.7 Liposomal formulation downregulates TRPA1 mediated ICAM-1 protein expressions in spinal cord of neuropathic rats	204
6.8 Liposomal formulation downregulates TRPA1 and IL-6 mRNA expressions in DRG of neuropathic rats	206
6.9 TRPA1 siRNA formulations does not affect locomotor activity and motor coordination of rats	208
Chapter 7: Summary & Conclusions	212-219
7.1 Summary	212
7.2 Conclusion	217
7.3 Limitations and outlook for future work	218
References	220-242
List of Publications and Conferences Attended	243-248
Brief Bio-Sketch	249-250